Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1). Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravi, Rajani, Noonan, Kimberly A., Pham, Vui, Bedi, Rishi, Zhavoronkov, Alex, Ozerov, Ivan V., Makarev, Eugene, V. Artemov, Artem, Wysocki, Piotr T., Mehra, Ranee, Nimmagadda, Sridhar, Marchionni, Luigi, Sidransky, David, Borrello, Ivan M., Izumchenko, Evgeny, Bedi, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821872/
https://www.ncbi.nlm.nih.gov/pubmed/29467463
http://dx.doi.org/10.1038/s41467-017-02696-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821872/
https://www.ncbi.nlm.nih.gov/pubmed/29467463
http://dx.doi.org/10.1038/s41467-017-02696-6

Ejemplares similares